During the last few years of the pandemic, the problem of bacterial resistance has become more evident to the point of becoming a threat to life.
Since 2019, the World Health Organization (WHO) has invited nations to act preventively against the inappropriate use of antibiotics, since otherwise by 2050 drug-resistant diseases could cause 10 million deaths annually.
Given this scenario, specialists such as Dr. Antonio Arista Viveros, a pediatric infectologist, point out that the indiscriminate use of antibiotics and self-medication are the main causes for bacteria to evolve and their treatments to suffer complications, causing long hospital stays, which increases costs and they even increase the mortality of patients.
Non-antibiotic options to avoid bacterial resistance
Currently in Mexico an effort is made through continuous medical updating to spread and invite doctors to use non-antibiotic options such as sublingual immunotherapies, made from inactivated whole bacteria,
“This is a key differentiator to optimally train the immune system at the time of infection,” said Dr. Antonio Arista Viveros.
Compared to bacterial lysates, which only preserve fragments of the bacteria, the immunotherapies brought to Mexico by the Carnot Laboratoriesthey preserve the complete genetic material, which allows an optimal recognition of the immune system.
Dormant bacteria work as training for the immune system
The selection of inactive bacteria responds to those most frequently related to respiratory infections, such as: Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus epidermidis, Klebsiella pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae.
During the medical sessions held in Mexico City, it is specified that the sublingual technology of these new immunotherapies is safe and effective due to its direct absorption by the immune system to prevent respiratory infections in the case of the MV-130 product, and to prevent urinary tract infections in the case of MV-140.
Refering to sublingual immunotherapy directed to urinary tract the selection of the inactivated bacteria that they contain are Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris and Enterococcus faecalis, which makes MV-140 the first immunotherapy of its kind in Mexico specifically aimed at preventing recurrent urinary tract infections.
Urinary tract infections are currently the first cause of medical consultation in reproductive age, since more than 50% will suffer from them throughout their lives and up to 10% of cases will have recurrences.
Thanks to the innovation of sublingual immunotherapies, patients can benefit at any stage of their life from 6 months of age, thus improving the immune response and the synergistic effect between 12 and 18 months (supported by clinical studies published in scientific journals such as the News England Journal of Medicine and in the Frontiers of Immunology).
